



Simona Volovat

COMPETENȚE LINGVISTICE

Limbă(i) maternă(e):

română

engleză

COMPREHENSIVNE ORALĂ: C2 CITIT: C2 SCRIS: C2

EXPRIMARE SCRISĂ: C2 CONVERSAȚIE: C2

portugheză

COMPREHENSIVNE ORALĂ: C1 CITIT: C1 SCRIS: C1

EXPRIMARE SCRISĂ: C1 CONVERSAȚIE: C1

franceza

COMPREHENSIVNE ORALĂ: C1 CITIT: C1 SCRIS: C1

EXPRIMARE SCRISĂ: C1 CONVERSAȚIE: C1

germana

COMPREHENSIVNE ORALĂ: B1 CITIT: B1 SCRIS: A2

EXPRIMARE SCRISĂ: B1 CONVERSAȚIE: B1

EDUCAȚIE ȘI FORMARE PROFESIONALĂ

Medic

Universitatea de Medicina si Farmacie "Gr T Popa" Iasi [2003 – 2009]

Adresă: Iasi (România)

Doctorat

Universitatea de Medicina si Farmacie "Gr T Popa"

Adresă: Iasi (România)

Domeniul (domeniile) de studiu: Cancer colorectal

Media finală/ Rezultatul final : Excelent

Global Clinical Scholars Research Training Program

Harvard Medical School [06/2019 – 09/2020]

Domeniul (domeniile) de studiu: Biostatistica medicala, Design de trialuri clinice

Media finală/ Rezultatul final : Distinctie - Top 10 proiecte

Certificate of Competence in Breast Cancer

European School of Oncology - University of Ulm [03/2019 – 09/2020]

Domeniul (domeniile) de studiu: Certificare europeana pe cancerul de san

Media finală/ Rezultatul final : 9.4/10

EXPERIENȚA PROFESIONALĂ

Medic rezident

Universitatea de Medicina si Farmaci "Gr T Popa" Iasi [01/2010 – 12/2015]

Localitatea: Iasi

Medic rezident

Institutul Curie - Hopital Rene Huguenin [11/2011 – 11/2012]

Localitatea: Paris

Țara: Franța

Asistent universitar

Universitatea de Medicina si Farmacie "Gr T Popa" [09/2014 – În curs]

Localitatea: Iași

Medic specialist oncologie medicala

Institutul Regional de Oncologie [09/2016 – În curs]

Localitatea: Iași

Medic specialist oncologie medicala

Breast Unit- Champalimaud Clinical Center [07/2017 – 04/2018]

Localitatea: Lisabona

Țara: Portugalia

CONFERINȚE ȘI SEMINARE

6th International Summer school on Experimental and Clinical Oncology for Medical Students

[Viena, Austria, 07/2007 – 07/2007]

EORTC Winter Meeting on Gastrointestinal Cancer 5th edition

[Frankfurt, Germania, 03/2010 – 03/2010]

Expert Practice in Lung Cancer meeting

[Munchen, Germania, 04/2010 – 04/2010]

5th European international kidney cancer symposium

[Londra, Anglia, 05/2010 – 05/2010]

HHAC Hospitation Associated with Program for the Advancement of Therapy in Hepatocellular Carcinoma (PATH)

[04/2011 – 04/2011]

Prise en charge des sarcomes et des tumeurs conjunctives

[Paris, Franța, 05/2012 – 05/2012]

“Preceptorship on Angiogenesis in Colorectal Cancer and Other Cancers”

[Leuven, Belgium, 11/2012 – 11/2012]

XXVIII Cours de chimiotherapie antitumorale et traitement medical du cancer

[Paris, Franța, 01/2013 – 01/2013]

12th ESC Masterclass in Clinical Oncology

[Ermatigen, Elvetia, 03/2013 – 03/2013]

Tour d'Europe Preceptorship at Gustave Roussy Institute

[Paris, Franta, 06/2013 – 06/2013]

Course on Epidemiology

[Iasi, Romania, 10/2014 – 10/2014]

CERCETARE MEDICALA

Cercetare medicala

Sub- investigator si co-investigator in aproximativ 20 studii clinice

Membru in 2 granturi interne, 1 grant international si director de proiect in cadrul unui grant intern.

Indice Hirsch= 5

Publicatii

Autor a 16 articole cotate ISI, 11 articole cotate BDI, 14 capitole de carte. Titluri reprezentative:

1. **Volovat SR**, Volovat C, Scripcariu V, Lupascu C, Miron L. The results of combination of ifosfamid and locoregional hyperthermia (EHY 2000) in patients with advanced abdominal soft-tissue sarcoma after relapse of first line chemotherapy. *Rom Reports Phys.* 2014;66(1):175–81. ISSN: 1221-1451; [ISI IF- 1.517] http://www.rrp.infim.ro/2014_66_1/A19.pdf
2. **Volovat SR**, Volovat C, Negru SM, Danciu M, Scripcariu V. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis. *J Chemother.* Taylor & Francis; 2016 May 3;28(3):235–41. [ISI IF- 1.577] <https://www.tandfonline.com/doi/abs/10.1179/1973947815Y.0000000042?journalCode=yjoc20>
3. Volovat C, **Volovat SR**, Scripcaru V, Miron L. Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer- preliminary results of a prospective trial. *Rom Reports Phys.* 2014;66(1):166–74. ISSN: 1221-1451; [ISI IF- 1.517] http://www.rrp.infim.ro/2014_66_1/A18.pdf
4. Ribnikar D, **Volovat SR**, Cardoso F. Targeting CDK4/6 pathways and beyond in breast cancer. *The Breast.* 2019;43:8–17. Available from: <http://www.sciencedirect.com/science/article/pii/S0960977618303011> <https://doi.org/10.1016/j.breast.2018.10.001> [IF= 2.951]
5. Ghimpau V, Lungulescu C, Grecu A, Gheonea D et al. Correlations Between Distinct Ras Mutations and Response to Bevacizumab in Patients with Colo-rectal Cancer. *Rev Chim* 2019; 70(6). [IF 1.412] <http://www.revistadechimie.ro/pdf/69%20GHIMPAU%206%2019.pdf>
6. Ureche C, Tapoi L, Volovat S, Voroneanu L, Kanbay M, Covic A. Cardioprotective apelin effects and the cardiac-renal axis: review of existing science and potential therapeutic applications of synthetic and native regulated apelin. *J Hum Hypertens.* 2019 Jan 18; <http://www.ncbi.nlm.nih.gov/pubmed/30659278>
- 7.L. Pires Novais Dias, J. Ribeiro, E. Batista, D. Pinto, M.J. Brito, M.A. Vasconcelos, P. Gouveia, B. Sousa, S. Volovat, M. Chumbo, C.M. Mavioso, O. Freitas Melro Braghiroli, M. Possanzini, J. Hernandez, C. Alves, M.J. Cardoso, F. Cardoso *MRI for monitoring breast cancer response to neoadjuvant chemotherapy.* *Eur J Cancer* 92; Suppl 3 (2018), S17-S160 [ISI IF- 6.029]
- 8.Volovat S, Ribeiro J, Sousa B, Cardoso MJ, Cardoso F. *BRCA mutations in young women – overview of a tertiary Breast Unit* *The Breast* Volume 29, Supplement 1, Pages S1-S38 (November 2016) BCY3 - 3rd ESO-ESMO Breast Cancer in Young Women International Conference [ISI IF-2.38]
9. Andre, R., Volovat, S. and Cardoso, F. (2017). Treatment of advanced disease: Guidelines. In: U. Veronesi, A. Goldhirsch, P. Veronesi, O. Gentilini and M. Leonardi, ed., *Breast Cancer Innovations in Research and Management.* Springer, pp.549-557.

